Beam Therapeutics, a Cambridge, Mass.-based biotechnology company developing precision genetic medicines through base editing, completed a $135m Series B financing.
Backers included new investors Redmile Group, Cormorant Asset Management, GV, Altitude Life Science Ventures, and additional undisclosed investors, along with existing investors F-Prime Capital, ARCH Venture Partners, Eight Roads Ventures, and Omega Funds.
The company intends to use the funds to advance development of next-generation CRISPR technologies, expand its pipeline of base editing programs, and further extend its scientific and technical leadership.
Led by John Evans, chief executive officer, Beam Therapeutics is developing precision genetic medicines through base editing. Founded by scientists in CRISPR gene editing, the company is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA.